Quarterly results - GSK
WEBFind the latest financial performance announcement and historical materials for GSK's quarterly results. Download slides, transcripts, reports and infographics for Q1 2024 …
See results only from gsk.comSecond quarter 2024
GSK delivered a strong first half 2024 performance with excellent business …
Press release Third quarter 2…
GSK delivers strong Q3 sales of £9.1 billion +5% AER, +10% CER Total EPS 23.3p …
Investors
Find the latest Annual Report 2023 and Q2 2024 results of GSK, a global healthcare …
Investors | GSK
WEBFind the latest Annual Report 2023 and Q2 2024 results of GSK, a global healthcare company. Learn about GSK's growth, dividend, share price, ESG and investor events.
TRENDING ON GSK
WEBGSK delivered a strong first half 2024 performance with excellent business momentum, including increased sales growth of Specialty Medicines, particularly reflecting …
GSK sees strong growth as Haleon split and vaccine …
WEBJan 31, 2024 · GSK beat market estimates for fourth-quarter results on Wednesday, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs pipeline, underscoring the...
GSK beats expectations, shingles vaccine bolsters outlook
WEBFeb 1 (Reuters) - GSK (GSK.L) on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix and unveiled an …
GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, +32
WEBJun 23, 2021 · GSK reports strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER, and improved operating margin and Adjusted EPS. The company also provides …
Cost discipline supports delivery of Adjusted EPS of …
WEBFeb 9, 2022 · Highlights. Full results announcement (PDF) Download the FY 2021 results announcement. FY 2021 results announcement (PDF, 1.1MB) Strong commercial execution drives growth across …
WEBGSK delivers strong Q3 sales of £9.1 billion +5% AER, +10% CER Total EPS 23.3p -7% AER, +3% CER; Adjusted EPS 36.6p +3% AER, +10% CER 2021 full year EPS …
GSK's fourth-quarter results beat market estimate, sees 2024 growth
WEBJan 31, 2024 · GSK beat market estimates for fourth-quarter profit and sales on Wednesday, underpinned by a strong launch of its respiratory syncytial virus (RSV) …
GSK stays strong as healthy sales beat expectations | Reuters
WEBApr 26, 2023 · GSK began 2023 with a quarterly performance that beat analyst expectations and extended a series of positive results thanks to strong sales of its vaccines as well …
Skip to content
